The companies use ViGeneron-owned vgAAV, engineered AAV capsules to efficiently transplant retinal cells through intravitreal injection. This gene therapy platform allows less aggressive treatment administration.
Within the collaboration, ViGeneron fully exploits and validates in vitro therapeutic candidates for an undiagnosed target to treat acquired eye disease. Biogen reserves the right to add an additional reserved target within two years after the effective date. The companies work together on in vivo concept proof studies. Biogen will then be responsible for all other development and commercialization activities for the selected medical candidates.
ViGeneron will receive an advance payment and undisclosed research and development funding for the agreed work plan. In addition, ViGeneron will be eligible for development, regulatory and commercial milestone payments, as well as serial realms on net commercial sales of products arising from the collaboration.
Copyright © 2021 scienceboard.net